Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2016, 25(4):273-276

Inhibition of neprilysin - new horizon in heart failure therapy

Šimko F1,2, Dukát A3
1 Ústav patologickej fyziológie
2 III. interná klinika, Lekárska fakulta UK, Bratislava, Slovenská republika
3 II. interná klinika, Lekárska fakulta UK, Bratislava, Slovenská republika

Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šimko F, Dukát A. Inhibition of neprilysin - new horizon in heart failure therapy. Cardiology Letters. 2016;25(4):273-276.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)

    • References

    1. Braunwald E. The management of heart failure: the past, the present, and the future. Circ Heart Fail 2008;1:58-62. Go to original source...
    2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402. Go to original source...
    3. Simko F. Patomechanizmus zlyhania srdca. In: Hulín et al. Patofyziológia. Bratislava: Slovak Academic Press; 2002;520-530.
    4. Tendera M. Epidemiology, treatment, and guidelines for the treatment of heart failure in Europa. Eur Heart J 2005;(Supll 1)7:J5-J9. Go to original source...
    5. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011;(Suppl 2)13:13-17. Go to original source...
    6. Turcani M, Fizell A, Maasova D, et al. The pathophysiology of heart failure. Bratisl Lek Listy 1988;3:211-219.
    7. Simko F. Zlyhanie srdca. In: Kiňová S, Hulín et al. Interná medicína. Bratislava: ProLitera; 2013:265-282.
    8. Simko F. Patofyziológia. In: Goncalvesová et al. Zlyhávanie srdca. Bratislava: ProLitera; 2015:71-82.
    9. McMurray J, Cohen-Solal A, Dietz R, et al. Clinical Research Initiative in Heart failure. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail 2001;3:495-502. Go to original source...
    10. Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 1999;48:1-8.
    11. Simko F, Simko J, Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther 2003;17:287-290. Go to original source...
    12. Simko F. Patofyziologické princípy terapie srdcového zlyhania. In: Hulín et al. Patofyziológia. Bratislava: Slovak Academic Press; 1998:396-402.
    13. Clark AL, Cleland JG. The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev 2000;5:101114. Go to original source...
    14. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016:735-1097. Go to original source...
    15. Simko F, Paulis L. Hypertensive heart disease: bone marrow as a significant player in pathologic remodelling? J Hypertens 2012;30:1702-1705. Go to original source...
    16. Simko, F, Pechanova O, Pelouch V, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens 2009;(Suppl.6)27:S5-S10. Go to original source...
    17. Simko F, Pechanova O, Pelouch V, et al. Continuous light and L-NAME - induced left ventricular remodelling: different protection by melatonin and captopril. J. Hypertens 2010;(Suppl 1)28:S13-S18. Go to original source...
    18. Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 2010;(Suppl 1)28:S1-S6. Go to original source...
    19. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest 2007;37:681-691. Go to original source...
    20. Simko F, Bednarova K, Krajcirovicova K, et al. Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. J Pineal Res 2014;57:177-184. Go to original source...
    21. Dzau VJ. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol 1992;70:4C-11C. Go to original source...
    22. Simko F. Left ventricular hypertrophy regression as a process with variable biological implications. Can J Cardiol 1996;12:507551.
    23. Simko F, Paulis L. Antifibrotic effect of melatonin. Perspective protection in hypertensive heart disease. Int J Cardiol 2013;168:2876-2877. Go to original source...
    24. Brunner-La Rocca HP, Fleischhacker L, Golubnitschaja O, et al. Challenges in personalised management of chronic diseasesheart failure as prominent example to advance the care process. EPMA J 2016;7:2. Go to original source...
    25. Packer M. The impossible task of developing a new treatment for heart failure. J Card Fail 2002;8:193-196. Go to original source...
    26. Simko F, Matuskova J, Luptak I, et al. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004;74:1211-1224. Go to original source...
    27. Simko F, Pechanova O, Krajcirovicova K, et al. Effects of captopril, spironolactone, and simvastatin on the cardiovascular system of non-diseased Wistar rats. Int J Cardiol 2015;190:128-130. Go to original source...
    28. Chen HH, Glockner JF, Schirger JA, et al. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol 2012;60:2305-2312. Go to original source...
    29. McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail 2015;17:242-247. Go to original source...
    30. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920926. Go to original source...
    31. Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, doubleblind, placebo-controlled, active comparator study. Lancet 2010;375:1255-1266. Go to original source...
    32. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-955. Go to original source...
    33. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. Go to original source...
    34. Packer M, McMurray JJ, Desai AS, et al. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131:54-61. Go to original source...
    35. Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-1395. Go to original source...

    Return to the content